

Treatment of uncomplicated childhood malaria by artemether-lumefantrine (Coartem®) efficacy, effectiveness, safety and genotyping in Tanzania

Submission date 17/04/2007	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 03/05/2007	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 22/03/2013	Condition category Infections and Infestations	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Olumide Ogundahunsi

Contact details
Manager
MIM/TDR Task Force on Malaria Research Capability Strengthening in Africa
World Health Organization
20 Avenue Appia
Geneva-27
Switzerland
CH-1211

Additional identifiers

Protocol serial number
A60100

Study information

Scientific Title

Study objectives

The effectiveness of Coartem® would be equal to efficacy given good compliance.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approval received from the ethics board of the National Institute of Medical Research Board on the 1st August 2006 (ref: NIMR/HQ/R.8a/Vol. IX/344).

Primary study design

Interventional

Study design

Clinical research

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Malaria in under five children

Interventions

In this clinical trial there is no intervention apart from early diagnosis and prompt treatment.

Patients will be treated with Artemether-lumefantrine (Coartem®), given either under supervision or by their parents. Treatment with Coartem® will be for three days, and the patients will be followed up on the following days:

Under supervision: follow-up on days 1, 2, 3, 7, 14, 21, 28, 35, 42, 49, 56

Drugs given by parent: follow-up on days 1, 7, 14, 21, 2, 35, 42, 49, 56

If the treatment is a clinical failure after day 14, or a parasitological failure after day 56, then the patient will again be treated for three days with Coartem®, and will be followed up on the following days:

Under supervision: follow-up on days 1, 2, 3, 7, 14, 21, 28, 35, 42

Drugs given by parent: follow-up on days 1, 7, 14, 21, 2, 35, 42

If the treatment is a clinical failure after day 14, or a parasitological failure after day 42, then the patient is treated with quinine.

Principal Investigator:

Professor Zul Premji

Muhimbili University College of Health Sciences

Box 65011

Dar es Salaam

United Republic of Tanzania

Tel: +255 (0)754 304 468
Email: zpremjji@muchs.ac.tz

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Artemether-lumefantrine (Coartem®)

Primary outcome(s)

Polymerase Chain Reaction (PCR)-adjusted parasitological treatment response (cure, treatment failure) on days 14, 28, 42 and 56 after initial treatment, and on days 14, 28 and 42 after retreatment in supervised and unsupervised patients.

Key secondary outcome(s)

1. Occurrence of adverse events during 56 and 42 days after initial and retreatment
2. Recrudescence after initial and retreatment
3. Reinfection after initial treatment

Completion date

01/12/2009

Eligibility

Key inclusion criteria

1. Males or females less than five years of age with body weight greater than 5 kg
2. Suffering from acute uncomplicated *P. falciparum* malaria confirmed by microscopy using Giemsa-stained thick film with an asexual parasite density of 2,000 to 200,000 parasites/ μ l
3. Presenting with fever (axillary temperature equal to 37.5°C) or having a history of fever in the preceding 24 hours
4. Able to ingest tablets orally (either suspended in water or un-crushed with food)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Upper age limit

5 Years

Sex

All

Key exclusion criteria

1. Present with any of the danger signs of severe malaria
2. Signs/symptoms indicating severe/complicated malaria according to World Health Organization (WHO) criteria (WHO definition)
3. Serious gastrointestinal disease, severe malnutrition (Weight-for-Height [W/H] less than 70%) or severe anaemia (haemoglobin less than 5 g/dl)
4. Known hypersensitivity to artemether-lumefantrine
5. Have been treated with any other drugs within eight weeks prior to screening or intend to use other drugs or biologics during the study

Date of first enrolment

01/03/2007

Date of final enrolment

01/12/2009

Locations

Countries of recruitment

Switzerland

Tanzania

Study participating centre

Manager

Geneva-27
Switzerland
CH-1211

Sponsor information

Organisation

UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)

ROR

<https://ror.org/01f80g185>

Funder(s)

Funder type

Research organisation

Funder Name

Multilateral Initiative on Malaria (MIM)

Funder Name

United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)
/World Bank/World Health Organization (WHO) - Special Programme for Research and Training
in Tropical Diseases (TDR)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/04/2011		Yes	No
Results article	results	18/03/2013		Yes	No